Imugene CEO & Managing Director Leslie Chong will present on Wednesday, 19 March 2025, at 9:00 AM AEDT as part of the NWR Communications Virtual Healthcare Conference. Date: Wednesday, 19 March 2025 Time: 9:00 AM AEDT Register here: tinyurl.com/5as39va8 A recording will be

REMINDER | Imugene CEO & Managing Director Leslie Chong will present tomorrow (19 March 2025), at 9:00 AM AEDT as part of the NWR Communications Virtual Healthcare Conference. Date: Wednesday, 19 March 2025 Time: 9:00 AM AEDT Register here: tinyurl.com/5as39va8 A recording will be

We've been granted Fast Track Designation by the U.S. FDA for our allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma. This designation is designed to facilitate the development and expedite the review process for

Imugene secures FDA fast track designation for CAR T-cell therapy azer-cel to combat blood #cancer | $IMU Media coverage by Proactive Australia. proactiveinvestors.com.au/companies/news…

Our CEO & MD Leslie Chong joins Proactive Australia to discuss the FDA’s Fast Track Designation for azer-cel, our allogeneic CAR T-cell therapy for relapsed/refractory DLBCL. With promising response rates and a growing clinical program, this designation supports expedited development

In case you missed it – CEO & Managing Director Leslie Chong's presentation at the NWR Communications Healthcare Conference is now available to watch. 🎥 Watch the $IMU replay here: youtu.be/WBMJCie3WME?si… #Imugene #Biotech #ASX #Healthcare NWR Communications

📣 We're excited to share our March newsletter. This edition includes updates on our key clinical milestones for azer-cel, recent intellectual property milestones, and highlights from our latest Q&A sessions. We also welcome our new CFO, Darren Keamy, and highlight recent media

𝗠𝗲𝗲𝘁 𝗦𝗵𝗮𝗿𝗼𝗻 𝗬𝗮𝘃𝗿𝗼𝗺– 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝘁 𝗜𝗺𝘂𝗴𝗲𝗻𝗲 Sharon brings extensive experience in oncology drug development, having contributed to therapies like Yervoy, Nivolumab, Nerlynx, and XGEVA. She has

We've cleared the first dose level in the intravenous (IV) combination arm of our Phase 1 onCARlytics trial. The study, known as OASIS, is targeting adult patients with advanced or metastatic solid tumours and is evaluating the safety and efficacy of intravenous and

Imugene clears first IV dose level in Phase 1 onCARlytics trial for solid tumours | $IMU Media coverage by Proactive Australia. proactiveinvestors.com.au/companies/news…

We're hosting a webinar for shareholders, investors, and anyone interested to share the latest company updates and answer some of the most frequently asked questions. The webinar will be hosted by Executive Chairman Paul Hopper, and he will be joined by CEO & MD Leslie Chong and

Imugene’s Senior Director, Translational Research, Grey Wilkinson, presented our poster 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑜𝑓 𝐶ℎ𝑜𝑙𝑎𝑛𝑔𝑖𝑜𝑐𝑎𝑟𝑐𝑖𝑛𝑜𝑚𝑎 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑂𝑛𝑐𝑜𝑙𝑦𝑡𝑖𝑐 𝑉𝑖𝑟𝑢𝑠 𝐶𝐹33-ℎ𝑁𝐼𝑆 yesterday at the 2025 Cholangiocarcinoma Foundation Annual Conference

REMINDER | Tomorrow, we're hosting a webinar for shareholders, investors, and anyone interested to share the latest company updates and answer some of the most frequently asked questions. The webinar will be hosted by Executive Chairman Paul Hopper, and he will be joined by CEO

The replay of our April 2025 Investor Update & FAQ Webinar is now available. Executive Chairman Paul Hopper, Managing Director & CEO Leslie Chong and Chief Operating Officer Bradley Glover responded to shareholder questions and provided updates across Imugene’s programs. Watch

Our Quarterly Activities Report for the period ending 31 March 2025 has been released. View the full $IMU report here: wcsecure.weblink.com.au/pdf/IMU/029409… #IMU #Imugene #Biotech #ASX #ASXNews

📰Imugene advances clinical programs with strong trial results and Fast Track status for azer-cel in quarter | $IMU Media coverage by Proactive Australia. proactiveinvestors.com.au/companies/news…

This Clinical Trials Day, we recognise the patients, investigators, and clinical trial teams and especially the patients who make our work possible. At Imugene, our mission to develop innovative cancer therapies relies on the strength of the data from our clinical trials from

We've released a letter to shareholders from CEO & MD Leslie Chong outlining the proposed 34:1 share consolidation and upcoming EGM on 26 June 2025. Read the full $IMU letter here: wcsecure.weblink.com.au/pdf/IMU/029510…

We've appointed Dr John Byon as Chief Medical Officer at Imugene. Dr Byon has extensive experience leading the clinical development of innovative CAR-T and CAR-NK therapies for multiple hematologic malignancies at Fate Therapeutics, Lyell Immunopharma, Juno Therapeutics as well

“As Chief Medical Officer, I’m focused on building on the momentum we’ve created, especially with Azer-cel. The early results show real potential for patients with limited options, and I’m committed to progressing our pipeline with that purpose in mind.” – Dr. John Byon, MD,